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published algorithm for the SF-36 generic instrument allowed the
calculation of utility scores for quality of life suitable for calcu-
lating QALYs. Standard statistical techniques, including multiple
imputation approaches to handle missing data, were employed
to address missing data issues allowing the estimation of cumu-
lative costs and QALYs over the three year study period.
RESULTS: In the base case analysis we estimated the incremen-
tal costs of FP versus placebo to be GBP929 (95% conﬁdence
interval (CI): GBP633 to 1220) with an additional effect of 0.14
QALYs (CI: 0.07 to 0.20). This generates a cost-effectiveness
estimate for the within-trial period of GBP6830 per QALY
gained (CI: GBP3960 to 13,300/QALY gained) which includes
uncertainty due to the imputation process. An alternative impu-
tation approach did not materially affect this estimate. CON-
CLUSIONS: Previous analyses of the ISOLDE study showed
signiﬁcant improvement on disease speciﬁc health status mea-
sures and a trend towards a survival advantage for treatment
with FP. This analysis shows that joint considerations of quality
of life and survival result in a substantial increase in QALYs in
favor of FP. Based on these data, FP appears cost-effective.
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Chronic obstructive pulmonary disease (COPD) is primarily a
disease of the elderly with increasing worldwide morbidity and
mortality. Goals of treatment are to relieve symptoms, reduce
airﬂow obstruction, and improve functioning. Although current
treatment strategies and guidelines for long-term COPD man-
agement recognize bronchodilators as ﬁrst-line therapy for all
patients, inhaled corticosteroids are prescribed for some patients.
OBJECTIVE: To characterize COPD medication prescribing pat-
terns among visits of patients >=65y across US ambulatory care
centers. METHODS: Data from the 2002 National Ambulatory
Medical Care Survey and the National Hospital Ambulatory
Medical Care Survey gathered from physician ofﬁces, hospital
outpatient, and emergency departments were analyzed for
patients >=65y. COPD visits were identiﬁed by primary diag-
noses of bronchitis, chronic bronchitis, emphysema, or chronic
airway obstruction. Patients with coexisting asthma were
excluded. Sample data were weighted to provide national esti-
mates. RESULTS: In 2002, COPD accounted for 7.7 million
ambulatory care visits among patients >=65y. Of these visits,
54.6% were by females and 93.0% were by white patients.
COPD medications were prescribed at 38.7% of visits with 
an average of 1.8 COPD medications prescribed per visit. 
Bronchodilators, alone or in combination, were prescribed at 
2.0 million visits, representing 26.5% of visits. Prescribed 
bronchodilators were short-acting beta-agonists (16.4%), anti-
cholinergics (11.8%), methylxanthines (7.5%) and long-
acting beta-agonists (4.8%). Inhaled corticosteroids, alone or in
combination, were prescribed at 13.4% of visits. The most 
commonly prescribed COPD medication combination was 
short-acting beta-agonists with anticholinergics (6.9%). CON-
CLUSION: Ambulatory care center prescribing patterns suggest
that COPD medications may be under-prescribed in elderly
patients. Bronchodilators appear to be the most common COPD-
speciﬁc treatment. The frequency with which short-acting beta-
agonists and anticholinergics were prescribed concurrently in
this dataset may indicate a deﬁciency in acceptable therapies that
provide sufﬁcient bronchoconstriction relief. Further research is
needed to assess optimization of drug management for elderly
COPD patients.
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OBJECTIVE: Until recently, primary prevention of sudden
cardiac death depended on anti-arrhythmic drugs. The SCD-
HeFT Trial conﬁrmed the efﬁcacy of ICD, as all-cause mortality
was decreased 23% versus placebo. Estimating lives saved and
economic impact of primary prevention of sudden cardiac death
with an ICD versus amiodarone in France was the object of this
study. METHODS: A discrete event simulation was developed
to estimate effects over three years. Identical patients received
either device or amiodarone. Post-implantation complications
(lead and device-related) or toxicity from amiodarone could
arise. Model parameters and risk functions were developed based
on SCD-HeFT data, assuming life-threatening arrhythmia rates
and other death are not differential. Probability of death given
arrhythmia was 90% with amiodarone, 47% with ICD. To avoid
ageism inherent in QALYs, the economic value society places on
a life (5,697,127€) was derived from a meta-analysis and used
in cost-beneﬁt analyses. While estimates of the value of life vary
from country to country, this value reﬂects a recent average for
European countries. Costs are reported in 2004 € and discounted
at 3%. In total, 100 replications of 1000 identical twin pairs
were run. Sensitivity analyses were performed for key input para-
meters. RESULTS: ICD use in 1000 patients was predicted to
prevent 62 premature deaths over three years. Total additional
costs accrued were 20,121€ per patient. The cost/beneﬁt ratio
was 0.06 which means for every 1€ gained, 0.06€ has to be
invested. In 55% of the replications ICD dominates Amiodarone.
Investment in ICD is worthwhile whenever society values a life
at more than 325,000€. CONCLUSION: ICDs increase imme-
diate costs but their use is consistent with the value of life esti-
mated in Western societies.
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OBJECTIVE: To compare effectiveness of rosuvastatin to ator-
vastatin on lipid levels (LDL-C, HDL-C, triglycerides, total 
cholesterol) and LDL-C goal attainment. METHODS: Patients
newly-initiated on rosuvastatin or atorvastatin between August
1, 2003 and June 30, 2004 were identiﬁed from a West Coast
health plan’s claims data for this retrospective, longitudinal
cohort study. Patients were excluded if they had any dyslipidemic
therapy 12-months preceding their initial statin ﬁll. Propensity
score matching on baseline characteristics was used to minimize
